CardioTech Announces Conference Call on November 13 at 2:30 PM Eastern For Second Quarter of Fiscal 2008

WILMINGTON, Mass., Nov. 5 CardioTechInternational, Inc. (Amex: CTE), a developer and manufacturer of advancedmaterials and medical devices for the treatment of cardiovascular and otherdiseases, announced today that it will release its fiscal 2008 second quarterfinancial results before the market opens on Tuesday, November 13, 2007.Following the release, the Company will host a conference call for investorsat 2:30 p.m. ET (11:30 a.m. PT) to discuss its fiscal second quarter results.

Participants should dial-in (866) 835-8845 Conference ID# 1155065 or(703) 639-1408 outside the U.S. Please dial-in 10 minutes before the call isscheduled to begin. A replay of the call will be available for two weeksfollowing the call at (888)-266-2081 ID# 155065 and on the Company's website.

About CardioTech International:

CardioTech is a developer of advanced polymer materials and manufacturerof medical products for the treatment and diagnosis of a broad range ofdisease states. The Company's business model leverages its proprietarymaterials science technology and manufacturing expertise in order to expandits product sales and royalty and license fee income. It develops nextgeneration polymers and manufactures new and complex medical devices tocustomers' unique specifications. CardioTech is conducting its first clinicaltrial for regulatory approval in Europe for its CardioPass synthetic coronarybypass graft. More information about CardioTech is available at its website:http://www.cardiotech-inc.com.For Further Information Contact: Eric Walters Sylvia Dresner Vice President & Chief Financial Officer Senior Vice President CardioTech International, Inc. VMW Corporate & Investor 978-657-0075 Relations [email protected] 212-616-6161 [email protected]

SOURCE CardioTech International, Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...